Company Active LTD

Company profile

Caristo Diagnostics Limited

Caristo Diagnostics

Caristo Diagnostics Limited is a UK company with status active founded in 2018 based in South East England.

CRN
11429590
Founded
2018
Age
8

Overview

Legal name
CARISTO DIAGNOSTICS LIMITED
Region
South East England
Registered address
NEW BARCLAY HOUSE
234 BOTLEY ROAD
OXFORD
UNITED KINGDOM
OX2 0HP
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

7 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

05 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

21 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

07 Nov
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MjM3ODA1N2FkaXF6a2N4

Published 07 Nov 2024 01:32

13 Oct
2024

Accounts With Accounts Type Small

Accounts PDF pending

AA | Transaction MzQzODczMzg4NmFkaXF6a2N4 | Paper/PDF filed

Published 15 Oct 2024 06:04

22 Jun
2018

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2019
Funded years
2019, 2020
Age at first award
0 years

Projects

2020 Feasibility Studies Lead participant

A new technology to transform cardiac risk management by imaging coronary artery inflammation

1 Jun 2020 to 31 Mar 2021

Awarded
£139,086
Total cost £139,086

no public description

2019 Collaborative R&D

National Consortium of Intelligent Medical Imaging (NCIMI)

1 Jan 2019 to 31 Mar 2023

Awarded
£0
Total cost £250,700

"We have formed a consortium of collaborating hospitals and commercial companies with public and patient involvement and input from charities to enable us to work with the public and the NHS to best develop and test the use of Artificial Intelligence programmes to improve health care. We are working with university academics and NHS hospitals across the c...

Product types

Collaborative R&D Feasibility Studies